Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 200 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dexmedetomidine film for agitation in schizophrenia	Dexmedetomidine	Schizophrenia	Mental and Behavioural Health	2022	View \| Download
Dimethyl fumarate for relapsing remitting multiple sclerosis in people aged 13 years and older	Dimethyl fumarate (FP-187)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Donanemab for treating early symptomatic Alzheimer's disease	Donanemab	Alzheimer's disease	Neurology	2022	View \| Download
Dupilumab for treating Chronic obstructive pulmonary disease (COPD)	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic obstructive pulmonary disease (COPD)	Respiratory System	2022	View \| Download
Dupilumab for treating eosinophilic oesophagitis in people aged 12 years and older	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Eosinophilic oesophagitis	Gastroenterology , Immunology	2022	View \| Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Cervical cancer	Female Reproductive Cancer	2022	View \| Download
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab for limited stage small-cell lung cancer after 1 therapy	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab with Bacillus Calmette-Guerin for treating non-muscle invasive bladder cancer	Bacillus Calmette-Guerin (BCG; BCG Tokyo-172; OncoTICE) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Bladder cancer	Urological Cancer	2022	View \| Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download